Core Viewpoint - The increasing trend of funds focusing on inquiry transfer projects, which offer shorter cycles and greater discounts, is aimed at enhancing capital utilization efficiency [1]. Group 1: Market Trends - Since 2026, 12 listed companies have conducted inquiry transfers, with notable participation from well-known public and private fund institutions such as E Fund, Huaxia Fund, and Nord Fund [1][2]. - The inquiry transfer of Guangdong Wannianqing Pharmaceutical Co., Ltd. involved a maximum transfer of 8 million shares at a price of 18.80 CNY per share, reflecting a discount rate of 91.66% compared to the closing price on the pricing benchmark date [2][3]. Group 2: Participant Analysis - Private and public funds are the main participants in inquiry transfers, with private funds having the highest subscription frequency from 2020 to 2025, totaling 577 times [3]. - Public funds led with 82 subscriptions among licensed financial institutions, followed by QFII and securities companies with 43 and 60 subscriptions, respectively [3]. Group 3: Performance Metrics - As of February 11, 2026, 11 out of 12 companies that conducted inquiry transfers had stock prices above the initial transfer price, with some institutions achieving floating profits exceeding 30% [4]. - For example, Jiangbolong's inquiry transfer price was 212.09 CNY per share, while its stock price reached 284.14 CNY, resulting in a floating profit rate of approximately 34% [4]. Group 4: Comparative Analysis with Private Placements - Inquiry transfers have shown superior returns and discount performance compared to private placements, with an average return of 49.52% for inquiry transfers in 2025, surpassing the 38.61% return from competitive private placements [4][5]. - The number of companies conducting inquiry transfers increased from 12 in 2021 to 180 in 2025, indicating a growing acceptance of this method [5]. Group 5: Strategic Insights - Inquiry transfers and private placements complement each other by offering different risk-return profiles, attracting various investment strategies [5]. - The focus on sectors such as semiconductors, AI hardware, and domestic software is expected to enhance the visibility and growth certainty of leading companies, making their equity attractive assets [5].

证券代码：301111 证券简称：粤万年青 公告编号：2026-008 广东万年青制药股份有限公司 关于开立募集资金现金管理专用结算账户及使用部分闲置募 集资金（含超募资金）和自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东万年青制药股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日 召开第三届董事会第十次会议，并于 2025 年 12 月 31 日召开 2025 年第四次临 时股东会，审议通过了《关于使用部分闲置募集资金（含超募资金）和自有资 金进行现金管理的议案》，同意公司在确保不影响正常运营和募集资金投资项目 建设的情况下，使用不超过人民币 2.5 亿元（含 2.5 亿元）的闲置募集资金 （含超募资金）及不超过人民币 2.5 亿元（含 2.5 亿元）的自有资金进行现金 管理，上述额度自股东会审议通过之日起 12 个月内有效。在上述额度和期限范 围内，资金可循环滚动使用，并授权公司管理层在额度范围内行使相关决策权、 签署相关合同文件等。具体内容详见公司于 2025 年 12 月 16 日及 2025 年 ...

Core Viewpoint - The equity change involves Guangdong Jinou Health Technology Co., Guangdong Qiaoyin Real Estate Development Co., and Shantou Yinkang Enterprise Management Consulting Partnership, which collectively hold 76 million shares, representing 47.50% of the total share capital of the company [1] Summary by Relevant Categories Shareholding Structure - Guangdong Jinou Health Technology Co. holds 65.6 million shares, accounting for 41.00% of the total shares [1] - Guangdong Qiaoyin Real Estate Development Co. holds 10.4 million shares, representing 6.50% of the total shares [1] - Shantou Yinkang Enterprise Management Consulting Partnership no longer holds any shares [1] Transaction Details - The equity change was completed through centralized bidding, block trading, and inquiry transfer methods [1] - All shares involved are unrestricted circulating shares, with no pledges or freezes affecting rights [1] Control and Ownership - The equity change will not result in a change of the company's controlling shareholder or actual controller [1]

股东向特定机构投资者询价转让股份的核查报告 深圳证券交易所： 东吴证券股份有限公司（以下简称"东吴证券"或"组织券商"）受委托担 任广东金欧健康科技有限公司、广东侨银房地产开发有限公司（以下简称"出让 方"）以向特定机构投资者询价转让（以下简称"询价转让"）方式减持所持有的 广东万年青制药股份有限公司（以下简称"公司"或"粤万年青"）首次公开发行前 已发行股份的组织券商。 经核查，东吴证券就本次询价转让的股东、受让方是否符合《深圳证券交易 所上市公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让 股份（2025 年修订）》（以下简称"《询价转让和配售指引》"）要求，本次询 价转让的询价、转让过程与结果是否公平、公正，是否符合《询价转让和配售指 引》的规定作出如下报告说明。 一、本次询价转让概况 （一）本次询价转让出让方 截至 2026 年 2 月 3 日出让方所持公司首发前股份的数量及占公司总股本比 例情况如下： 东吴证券股份有限公司 关于广东万年青制药股份有限公司 | 序号 | 股东名称 | 持股数量（股） | 持股比例 | | --- | --- | --- | --- | | 1 | ...

广东万年青制药股份有限公司 简式权益变动报告书 上市公司名称：广东万年青制药股份有限公司 上市地点：深圳证券交易所 股票简称：粤万年青 股票代码：301111 信息披露义务人一：广东金欧健康科技有限公司 住所/通讯地址：汕头市龙湖区长江路 8 号 15 层 01 号房南侧 A21 信息披露义务人二：广东侨银房地产开发有限公司 住所/通讯地址：汕头市金平区玫瑰园南墩厂房 C 座三楼 313 信息披露义务人三：汕头市银康企业管理咨询合伙企业（有限合伙） 住所/通讯地址：汕头市龙湖区天山路 13 号 701-5 号房 C2 单元 股权变动性质：股份减少 签署日期：2026 年 2 月 10 日 1 信息披露义务人声明 一、本报告书系信息披露义务人依据《公司法》《证券法》《上市公司收购 管理办法》《证券期货法律适用意见第 19 号—<上市公司收购管理办法>第十三 条、第十四条的适用意见》和《公开发行证券的公司信息披露内容与格式准则第 15 号-权益变动报告书》等相关法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行不违反 信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 ...

证券代码：301111 证券简称：粤万年青 公告编号：2026-007 广东万年青制药股份有限公司 关于股东询价转让结果报告书暨股东权益变动触及5%整数 倍的提示性公告 股东广东金欧健康科技有限公司、广东侨银房地产开发有限公司（以下合 称"出让方"）及汕头市银康企业管理咨询合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 1、本次询价转让的出让方系广东金欧健康科技有限公司（以下简称"金欧 健康"）及其一致行动人广东侨银房地产开发有限公司（以下简称"侨银房地产"）， 本次权益变动主体为金欧健康、侨银房地产及汕头市银康企业管理咨询合伙企业 （有限合伙）（以下简称"银康管理"），合计持有广东万年青制药股份有限公 司（以下简称"公司"）5%以上股份。本次权益变动方式为股份减少，本次权益 变动后，权益变动主体拥有权益的股份占公司总股本的比例由 54.9858875%下降 至 47.50%（以下简称"本次权益变动"），权益变动触及 5%的整数倍； 2、金欧健康为公司控股股东，侨银房地产为公司持股 5 ...

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index up by 0.11%, the Shenzhen Component Index up by 0.65%, and the ChiNext Index also up by 0.65% as of midday [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day, with over 3,800 stocks rising [2] Sector Performance - Active sectors included lithium batteries, energy metals, humanoid robots, and fintech, while traditional sectors like liquor, retail, and AI application stocks weakened [1] - The Chinese medicine and chemical sectors showed notable gains, with the Chinese medicine sector rising by 2.52% [2][7] - The small metals sector rebounded, with stocks like Xianglu Tungsten and Zhangyuan Tungsten hitting the daily limit [7] Notable Stocks - Mingdiao Co. experienced significant trading activity, achieving a "limit-up" with nearly 700 million yuan in transactions and marking its fifth consecutive trading day of gains [3] - Jiangfeng Electronics saw a slight increase of 0.09% after announcing plans to acquire control of Kaide Quartz [9] Economic Indicators - The industrial development plan for traditional Chinese medicine aims for a collaborative development system by 2030, which may positively impact the sector [7]

Market Overview - A-shares showed resilience against external market pressures, with major indices recovering after a low opening, resulting in the Shanghai Composite Index rising by 4.40 points (0.11%) to 4080.31 points, the Shenzhen Component Index increasing by 90.46 points (0.65%) to 14043.17 points, and the ChiNext Index up by 21.17 points (0.65%) to 3281.45 points [1] Sector Performance - The chemical sector saw strong performance, with stocks like Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [1] - The humanoid robot concept stocks were active, with companies such as Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. also reaching the daily limit [1] - The non-ferrous metals sector showed signs of recovery, with Hunan Gold and Xianglu Tungsten hitting the daily limit [1] - The traditional Chinese medicine sector opened strong, with stocks like Te Yi Pharmaceutical reaching the daily limit [1] Policy Support - The Chinese government, through the Ministry of Industry and Information Technology and other departments, issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030, which is expected to boost the sector's growth [2] Price Dynamics - The price of disperse dyes surged due to a significant increase in the cost of upstream key intermediates, rising from 25,000 yuan/ton to 38,000 yuan/ton, a more than 50% increase, which is expected to drive up prices in the textile dyeing industry as demand increases post-Spring Festival [3] Market Challenges - The liquor sector faced downward pressure, with stocks like Huangtai Liquor hitting the daily limit down, attributed to a decline in demand following the consumption peak around the Spring Festival and increased competition leading to price cuts [4] - AI application stocks experienced declines, with companies like Yaowang Technology and Zhejiang Wenhu falling to the daily limit due to concerns over technology maturity and unclear business models [5] - The optical module and CPO sectors continued to adjust, with stocks like Yuanjie Technology and Xinyisheng dropping over 6% as market expectations normalized [6] Institutional Insights - Zhongjin Securities noted that despite external pressures, there are no typical bull market top signals in Chinese stocks, with ample liquidity and improving earnings, suggesting a continued positive outlook for Chinese asset revaluation [7] - Tianfeng Securities highlighted the fragility of market sentiment, indicating that any news could trigger short-term sell-offs, particularly in the gold market [7] - Huachuang Securities observed a strong recovery in consumer markets expected for the 2026 Spring Festival, driven by government-led consumption initiatives, suggesting potential growth in sectors like dining, tourism, and retail [7]

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Core Viewpoint - Guangdong Wannianqing (301111.SZ) has announced a preliminary transfer price of 18.80 yuan per share after soliciting bids from institutional investors, with the total number of shares to be transferred being 8 million [1] Group 1 - The transfer of shares has been fully subscribed by institutional investors [1] - The preliminary identified transferees are two institutional investors [1]